Emerging findings provide ample evidence that prostate cancer cells constitutively generate 5-lipoxygenase (5-LOX) metabolites from arachidonic acid, and targeted inhibition of 5-LOX inhibits generation of 5-LOX metabolites and promotes cell death. Here, ALOX5 is linked to prostate carcinoma.